[Brokerage Focus] HTSC maintains a 'Buy' rating on Peijia Medical (09996) and indicates that the penetration rate in the TAVR Industry market share is further on the rise.

Jinwu Financial News | HTSC released a Research Report stating that the negative impact of events on the trading of Peijia Medical (09996) this year has dissipated. The firm is Bullish on the company: 1) On the market level, it is seizing opportunities in the Industry to consolidate its TAVR market share; 2) On the pipeline level, new TAVR/TMV products are expected to be approved for market launch in 2025, and commercial sales are likely to continue climbing thanks to differentiated designs; 3) Operating efficiency is continuously improving. The firm stated that during this year, the company's TAVR Sector seized the opportunity presented by the restructuring of competitors, further increasing market share thanks to excellent product capabilities (the firm estimates the market share will reach 23-27% by 2024, exceeding 3,400).

King Wu Financial NewsDec 24 16:24 · Ratings

PEIJIA-B (9996.HK): Focus on the leader amidst the changes in the TAVR landscape.

The negative impacts of Peijia Medical's trading events in the year have dissipated, and the company is viewed as bullish: 1) On the market level, seizing industry opportunities to consolidate TAVR market share; 2) On the pipeline level, new TAVR/TMV products are expected to be approved and launched in 2025.

HTSCDec 23 20:02

Peijia Medical Completes First Compassionate Use Treatment of Aortic Valve Replacement Device

MT NewswiresNov 18 19:38

Peijia Medical-B (09996.HK): Successfully completed the first compassionate use of the TaurusTrioTM TAVR system in Hong Kong.

On November 18, Gelonghui reported that Peijia Medical-B (09996.HK) announced that recently, the group's product TaurusTrioTM transcatheter aortic valve replacement ("TAVR") system for the treatment of symptomatic severe aortic regurgitation ("AR") has successfully completed the first compassionate use in Hong Kong. By January 2024, the company has completed patient enrollment for the multi-center registration clinical trial of the TaurusTrioTM TAVR system conducted in China. Follow-up assessments for the subsequent phase are ongoing. The company expects to commercialize this product after obtaining regulatory approval in China.

Gelonghui FinanceNov 18 07:52

Peijia Medical-B (09996.HK): Yu Zhiyun resigns as a non-executive director.

Grainews November 1st | Peijia Medical - B (09996.HK) announced that Yu Zhiyun has resigned as a non-executive director and member of the board of directors' remuneration committee on November 1, 2024, with immediate effect. Yu Zhiyun resigned from his position to devote more time to other work matters. Yu Zhiyun will continue to serve as a consultant to the company.

Gelonghui FinanceNov 1 21:32

Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.

"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.

Zhitong FinanceOct 29 09:30